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ABSTRACT: Background: Spinocerebellar ataxia
type 14 is a rare form of autosomal dominant cerebellar
ataxia caused by mutations in protein kinase Cc gene.
Clinically, it presents with a slowly progressive, mainly
pure cerebellar ataxia.
Methods: Using next generation sequencing, we
screened 194 families with autosomal dominant cerebellar
ataxia and normal polyglutamine repeats. In-depth pheno-
typing was performed using validated clinical rating scales
neuroimaging and electrophysiological investigations.
Results:We identified 25 individuals from 13 families car-
rying pathogenic mutations in protein kinase Cc gene. A
total of 10 unique protein kinase Cc gene mutations have
been confirmed of which 5 are novel and 5 were previ-
ously described. Our data suggest that the age at onset
is highly variable; disease course is slowly progressive
and rarely associated with severe disability. However,
one third of patients presented with a complex ataxia
comprising severe focal and/or task-induced dystonia,
peripheral neuropathy, parkinsonism, myoclonus, and
pyramidal syndrome. The most complex phenotype is
related to a missense mutation in the catalytic domain in
exon 11.
Conclusion: We present one of the largest genetically
confirmed spinocerebellar ataxia type 14 cohorts contribut-
ing novel variants and clinical characterisation. We show
that although protein kinase Cc gene mutations present
mainly as slowly progressive pure ataxia, more than a third
of cases had a complex phenotype. Overall, our case series
extends the phenotype and suggests that protein kinase
Cc gene mutations should be considered in patients with
slowly progressive autosomal dominant cerebellar ataxia,
particularly when myoclonus, dystonia, or mild cognitive
impairment are present in the absence of polyglutamine
expansion.VC 2018 The Authors. Movement Disorders pub-
lished by Wiley Periodicals, Inc. on behalf of International
Parkinson and Movement Disorder Society.
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Autosomal dominant cerebellar ataxias are a het-
erogeneous group of neurodegenerative disorders.
Spinocerebellar ataxia type 14 (SCA14) is a very rare
form with an estimated incidence of 1% to 4% of all
autosomal dominant cerebellar ataxias.1,2 It is
caused by mutations in the protein kinase Cg gene
(PRKCG). Missense mutations are responsible for
most of SCA14 reported cases but deletions and
splicing variants have also been described.3,4 The
mutations are primarily located in the regulatory
domains C1 and C2, with C1 harboring the largest
cluster of pathogenic PRKCG variants.5 PRKCG is
expressed predominantly in Purkinje cells. Neurode-
generation in SCA14 is thought to result from defec-
tive aggregation and disrupted synaptic activity.6,7
Clinically, SCA14 presents with slowly progressive,
early-onset, mainly pure cerebellar ataxia.8 Some
complex ataxic phenotypes have been associated
with PRKCG mutations, including focal, task-
induced dystonia, myoclonus, and pyramidal syn-
drome in single cases or small cohorts.1,9
We describe the genetic and clinical analysis of one
of the largest genetically confirmed SCA14 cohorts
contributing novel variants and supporting the pheno-
typic heterogeneity of PRKCG mutations.
Methods
Subjects
Proband cases with autosomal dominant, mainly
pure, cerebellar ataxia were recruited with informed
consents. Most of the families were of European
ancestry (n5194, of which 190 were British, 3 Dan-
ish, and 1 Italian). All cases had comprehensive phe-
notyping performed by neurogenetics specialists.
Ataxia was quantified in 17 cases using the validated
Scale for Assessment and Rating of Ataxia (SARA).10
Pure phenotype was defined as cerebellar syndrome,
with brisk reflexes and neurogenic bladder accepted
as additional features. Complex phenotype was
defined as cases with cerebellar syndrome, plus at
least 1 other neurological sign that cannot be
explained by associated comorbidities. Disability
score was defined as follows: 05 asymptomatic,
15 able to walk but difficulty with running, 25uses
one stick and/or orthosis, 35 uses 2 sticks/walker,
45unable to walk, uses wheelchair.
Results from additional investigations were analyzed
where available: neuroimaging with brain magnetic
resonance imaging (MRI; n512), fluorodeoxyglucose
(FDG)-positron emission tomography (PET) (n5 2),
electromyogram or nerve conduction studies (n5 7),
and videography. The cases with symptomatic mem-
ory/cognitive complaints (n55) had formal cognitive
assessment performed by qualified neuropsychiatrists.
Genetic Testing
DNA was extracted and investigated under approval
of the joint ethics committee of UCL Institute of Neurol-
ogy and the National Hospital for Neurology and Neu-
rosurgery, London, UK (UCLH: 04/N034). Families IX
and XIII were tested with informed consent as part of a
clinical diagnostic evaluation (Centogene AG, Rostock,
Germany and Molecular Genetic Laboratory, Depart-
ment of Clinical Genetics, Rigshospitalet, University of
Copenhagen, Copenhagen, Denmark). Apart from 2
families (IX and XIII), the SCA1, 2, 3, 6, 17, Frataxin
(FXN)-repeat expansions, Junctophilin 3 (JPH3), and
common DNA polymerase gamma (POLG)-mutations
were excluded in all cases using standard diagnostic tech-
niques. Ataxia-telangiectasia mutated gene (ATM) kinase
activity and levels of radiation-induced chromosome
damage as well as aprataxin and senataxin levels were
normal in all complex cases.
In the research approach, a custom-sequencing panel
was designed to amplify the coding exons of PRKCG
using the Illumina Truseq custom amplicon kit following
the manufacturer’s protocol. Libraries were prepared
according to the standard protocols and then sequenced
using an Illumina MiSeq. Bioinformatics analysis
included alignment of reads to the hg19 genome build
using Novoalign (Novocraft, Selangor, Malaysia) and
variant calling using SAMtools (http://samtools.source-
forge.net/). Variant annotation was performed with
ANNOVAR,11 and coverage metrics were assessed using
an in-house modified Bedtools coverageBed script. After
mutation identification, all of the variants reported here
were confirmed using Sanger sequencing.
For every identified PRKCG mutation, we deter-
mined pathogenicity and novelty. Novel and very rare
(minor allele frequency<0.1%), coding/splicing, and
heterozygous variants that are predicted to be patho-
genic were considered as likely causal variants.12,13
For the missense variants, the prediction was based on
conservation across different species and assessing
novel amino acid changes in known pathogenic posi-
tions. Where possible, segregation was confirmed in
other family members.
Statistical Analysis
Two-tailed t-tests were used to assess the correlation
between disease duration and SARA score. P .05
was considered statistically significant.
Results
Genetic Analyses
From the 194 index cases, a total of 13 pathogenic
mutations in PRKCG (ENST00000263431) were con-
firmed. We identified 10 unique mutations, of which 5
were novel and 5 known pathogenic variants (Fig.
1A). A total of 9 mutations were unique to 1 kindred
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FIG. 1. Description of mutations identified in spinocerebellar ataxia type 14 (SCA14) cohort. (A) Description of all protein kinase Cc gene (PRKCG)
mutations identified in the study (ENST00000263431). (B) Schematic representation of the PRKCG gene with the mutations identified in our study.
The exons are represented approximately to scale. The introns are represented by a blue line between exons. The PRKCG protein’s regulatory func-
tional domains are indicated: blue5 cysteine-rich region C1 (cys1 and cys2); orange5Ca21 sensitive region (C2); purple5 the catalytic domain con-
taining kinase (C3) and substrate recognition (C4) regions. The novel mutations are indicated on the top and the known mutations on the bottom of
the figure. [Color figure can be viewed at wileyonlinelibrary.com]
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only. The most frequent mutation was the previously
reported c.303C>G (p.His101Gln) found in 4 of our
families. Three mutations were located in exon 1, 4
mutations in exon 4, and 2 mutations in exon 5 as
part of the regulatory domains C1a and C1b. One
mutation was located in the catalytic domain in exon
11 of PRKCG (Fig. 1B). All variants were missense
mutations.
Case VIII-1 had a novel heterozygous mutation
c.1372G>A (p.Ala458Thr) confirmed by Sanger
sequencing (Fig. 2A-C). This mutation is located at a
highly conserved amino acid position (Fig. 2D). In silico
tools predict disease-causing effects (Mutation Taster;
http://www.mutationtaster.org/) and a highly likely
protein function interference (Align-GVD, http://agvgd.
iarc.fr/) with a Combined Annotation Dependent
Depletion (http://cadd.gs.washington.edu/home) score
of 22.3 and a Genomic Evolutionary Rate Profiling
score of 3.4 (Fig. 2E). No other family members were
available for further testing.
Family XIII is a large Danish family with 6 affected
individuals. As part of a clinical diagnostic evaluation, a
novel heterozygous mutation in exon 5, the c.424T>G
(p.Cys142Gly) was identified. The mutation fully segre-
gated with the disease in the family. This mutation
is absent from all publicly available databases
FIG. 2. Genetic and clinical details of case VIII-1 presenting with an unusual phenotype of severe dystonia and peripheral neuropathy. (A) Family
tree. (B) Sagittal MRI of patient at age 65 showing mild cerebellar atrophy and thin cervical cord. (C) Sanger sequencing result of the novel mutation
c.1372G>A. (D) Conservation through species of the novel mutation c.1372G>A. (E) Frequency and in silico predictions of the heterozygous, novel
missense protein kinase Cc gene (PRKCG) mutation identified. aGERP, positive conservation scores represent a substitution deficit and indicate that
a site may be under evolutionary constraint. Negative scores indicate that a site is probably evolving neutrally. Positive scores scale with the level of
constraint, such that the greater the score, the greater the level of evolutionary constraint inferred to be acting on that site. bCADD, Combined
Annotation Dependent Depletion is a tool for scoring the deleteriousness of single nucleotide variants as well as insertion/deletions variants in the
human genome across a wide range of functional categories, effect sizes, and genetic architectures. GERP, Genomic Evolutionary Rate Profiling; D,
deleterious/damaging/disease-causing. [Color figure can be viewed at wileyonlinelibrary.com]
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(1000 Genomes Project, www.1000genomes.org14;
National Heart, Lung, and Blood Institute "Grand
Opportunity" (NHLBI GO) Exome Sequencing, evs.gs.-
washington.edu15; and Exome Aggregation Consor-
tium, http://exac.broadinstitute.org/16) and is predicted
to affect the Cys1 regulatory domain.
Case I-1 has a novel heterozygous change c.70A>G
(p.Ala24Thr) that segregated with disease in the fam-
ily. This change is located in a highly conserved amino
acid position in the regulatory C1a domain. Family VI
and family X presented novel amino acid changes in
known pathogenic positions c.317A>C (p.His106Pro)
and c.302A>G (p.His101Arg), respectively.
The other cases had previously described pathogenic
mutations in PRKCG that segregated with the disease.
Clinical Summary
SCA14 individuals included in our cohort presented
with variable disease onset and phenotype. The mean
age of onset was 30.6 years with a range from 3 to 66
years, revealing a high variability between and within
the families. Within families, an earlier onset was
observed in the offspring of affected parents; however,
we attribute this to recall and ascertain bias. An early
age of onset (defined as onset before 20 years of age)
was identified in 40% of cases. However, a late onset
(after the age of 50) was reported in 12% of cases (3/
25; Fig. 3A). Mean disease duration was 18 years
(range 1-52 years). The mean SARA score at the last
examination (for 17 cases with a SARA score) was
13.1, consistent with moderate severity. SARA scores
correlated positively with disease duration (P5 .02;
Fig. 3B), but not with age of onset. Disease onset was
related to gait or limb ataxia. Table 1 presents the
results of detailed clinical examination. Screening for
atypical features revealed a complex ataxia phenotype
in 36% (9/25) of cases presenting with ataxia and 1
additional neurological sign or combination of signs,
including severe focal dystonia, task-induced dystonia,
severe peripheral neuropathy, parkinsonism, myoclo-
nus, tremor, and pyramidal syndrome. Importantly,
cases VIII-1 and II-2 presented with the most complex
phenotypes (Supporting Information Videos 1 and 2).
Complex Phenotypes in SCA14
Case VIII-1 developed a slowly progressive ataxia
with onset in the mid-30s initially affecting dexterity
and gait. Cerebellar ataxia was associated with dysar-
thria, mild neurogenic bladder, slight forgetfulness,
and clumsiness of hands. At the age of 55 years, he
noted new intermittent shaking of his head. This dys-
tonic head tremor rapidly progressed toward severe,
constant dystonic posturing of the head and right
hand. Currently, his clinical findings consist of dys-
tonic head tremor with constant titubation of head at
rest, laterocollis to the left, and subsequent
hypertrophy of the right sternocleidomastoid associ-
ated with the underlying progressive cerebellar syn-
drome. A bilateral mild wasting of the small hand
muscles is noted together with absent reflexes and
severe peripheral neuropathy in the lower limbs (Sup-
porting Information Video 1). Nerve conduction stud-
ies showed a severe length-dependent axonal sensory
motor neuropathy and a muscle biopsy was suggestive
FIG. 3. Genotype-phenotype correlations in spinocerebellar ataxia
type 14 (SCA14). (A) Age of onset in an SCA14 cohort. (B) Correlation
between Scale for Assessment and Rating of Ataxia (SARA) score and
disease duration. (C) Complex phenotypes in SCA14. [Color figure can
be viewed at wileyonlinelibrary.com]
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of neurogenic changes only. The causes of acquired
peripheral neuropathy had been excluded. The brain
MRI showed cerebellar hemispheric and vermis
atrophy (Fig. 2B). Neuropsychometry testing
revealed mild cognitive dysfunction affecting the
anterior and subcortical functions. Formal neuro-
psychometry testing was also performed in 3 other
individuals from a large SCA14 family (XIII-3, XIII-
4, and XIII-5) as well as case IX-5. The 2 affected
individuals (XIII-3 and XIII-4) also reported cogni-
tive dysfunction with difficulties in concentration
and memory. Case XIII-3 is 57 years old and case
XIII-4 is 29 years old. No other cases had cognitive
problems identified or reported during clinical
examination and follow-up.
The second case presenting with focal dystonia (case
VII-1) had a slowly progressive ataxic syndrome asso-
ciated with “writer’s cramp,” currently treated with
regular Botox injections.
Case II-2 is a member of a large family that we have
described previously.17 He presented with gait and
limb ataxia when aged in his 20s. Around the same
time, he noticed problems initiating movements, such
as walking over a doorstep. The disease slowly pro-
gressed and 38 years later he presented with moderate
ataxia (SARA score 18) associated with pyramidal
syndrome, parkinsonism (Supporting Information
Video 2), mild rest, spontaneous, peri-oral myoclonus,
and neurogenic bladder. Interestingly, his family mem-
ber (II-1) presents with pure cerebellar ataxia demon-
strating evident intrafamilial heterogeneity.
One frequently associated sign in the complex phe-
notypes was myoclonus. Myoclonus was present in
12% of cases (3/25). This was clinically characterized
as occasional and mild, spontaneous myoclonus, facial
peri-oral in the case II-2; as facial mini-myoclonus
with slight finger/arm myoclonus in case X-5; and as
occasional truncal jerks in case XIII-6. The myoclonus
was identified within the first 2 years from disease
onset (cases X-5 and XIII-6) and remained mild in the
case with almost 40 years of disease duration (case II-
2). In all cases, the mild severity of myoclonus did not
mandate any treatment, and no further electrophysio-
logical investigations were performed.
A quarter of our cases had an associated pyramidal
syndrome in the lower limbs. Neurogenic bladder was
also present in these patients. In addition, 3 patients
presented with mild dysphagia. The other two thirds
of cases presented with pure cerebellar ataxia of vari-
able severity (Table 1).
MRI of the brain was available in 14 cases and showed
only mild to moderate cerebellar atrophy in all cases.
Two individuals had brain positron emission tomogra-
phy with 2-deoxy-2-[fluorine-18]fluoro-D-glucose inte-
grated with computed tomography that showed reduced
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Discussion
We studied a large cohort (n5 194) of mainly pure,
autosomal dominant cerebellar ataxia cohort negative
for trinucleotide repeats and identified 13 families with
disease-causing mutations in PRKCG with a variable
spectrum of disease phenotype and severity. Our data
suggests that PRKCG mutations have a frequency of
6.7% (13/194). Previous studies showed SCA14 fre-
quencies varying 1.5% to 7.5% in different ethnic
groups.1-3 Also, early studies screened only parts of the
gene, therefore some mutations may have been missed.2
In the 13 families with PRKCG mutations, we identi-
fied 10 unique pathogenic variants suggesting that recur-
rent PRKCGmutations are infrequent. All mutations are
missense variants and are located within a functional
domain. The majority of mutations are located in the
regulatory C1 domain, consistent with previous reported
data. The exact mechanism leading to disease in SCA14
is still unknown, and the simplistic loss-of-function
hypothesis would not fully explain the autosomal domi-
nant inheritance in the context of the Protein kinase C
gama (PKCg) knockout mouse that had only a mild
ataxia and did not show any morphological changes in
the cerebellum.18,19 In vivo experiments show that muta-
tions in the C1 domain decrease membrane binding,
membrane retention time, and substrate phosphoryla-
tion, resulting in sustained high levels of intracellular
Ca21 upon cell stimulation and aberrant intracellular
signalling.20 However, mutations in the catalytic domain
showed an exaggerated inhibitory effect of Ca21 entry in
mutant cells when compared with wild type and Ca21
influx was completely blocked.20 Therefore, it is becom-
ing more clear that both sustained high Ca21 influx as
well as inhibition of Ca21 influx is involved in SCA14
pathology depending on the functional domain that is
affected. Interestingly, it was shown recently that muta-
tions in the catalytic but not in the regulatory domain
also show inhibition of the dendritic development in
addition to a different pattern of the enzymatic activ-
ity.21 These findings together with the difference in
PKCg biological activity both in vitro and in vivo cell
assays show that mutations located in different func-
tional domains lead to disease through different mecha-
nisms with a mutation-specific SCA14-resulting
phenotype.20,22,23 Although less frequent, mutations in
the catalytic domain have been described to cause a
more complicated SCA14.2,20,24 Clinically, these muta-
tions have been associated with a wider age of onset
(childhood until late 60s) and a more complex phenotype
including higher rate of cognitive dysfunction, myoclo-
nus, dystonia, and reduced vibration sense (Table 2). In
our study, the genotype-phenotype correlation confirms
that the novel missense variant c.1372G>A
(p.Ala458Thr) located in the catalytic domain produced
the most complex and severe phenotype. We would like
to highlight the unusual presentation of ataxia associated
with a severe, time-deferred dystonic component and a
severe peripheral neuropathy in the context of the mis-
sense p.Ala458Thr. Dystonia has been previously
reported in SCA14 mainly described as focal, task-
induced dystonia.9 Our case series extends the phenotype
and supports the association of ataxia and dystonia in
SCA14. To our knowledge, severe peripheral neuropathy
has not been previously formally associated with SCA14;
however, several cases of reduced vibration loss were
reported in mutations affecting the regulatory domain
(Table 2). The association with severe peripheral neurop-
athy needs to be confirmed in larger cohorts.
Our data suggest that in the majority of cases, SCA14
has an onset from childhood to early adulthood, is
slowly progressive, and is rarely associated with severe
disability, consistent with previous reports.25 However,
about 12% of cases presented with a late-onset cerebel-
lar ataxia (>50 years old). The most common genetic
conditions with similar presentation in this age group are
usually caused by CAG repeat expansions SCAs (SCA 1,
2, 3, and 6) and Friedreich’s ataxia that require different
approaches for molecular diagnosis. Importantly,
although our cohort had a long mean disease duration
(18 years), the mean SARA score was consistent with
moderate severity, supporting a slow disease progression
course. The most severe SARA score was 22.5 in a
patient who had the disease for more than 50 years.
Therefore, an autosomal dominant cerebellar ataxia
with normal SCA repeats, especially when slow progres-
sion and predominantly pure phenotype is predominant,
should alert the physician to test for PRKCG mutations.
We show that next generation sequencing can further
contribute to diagnosis in cases of late-onset cerebellar
ataxia where the repeats are within normal ranges.
More than a third of the patients in our study presented
with a complex ataxia phenotype composing of severe
focal and/or task-induced dystonia, severe peripheral neu-
ropathy, parkinsonism, myoclonus, tremor, and/or pyra-
midal syndrome. This is consistent with previous reports
of complex cases of ataxia associated with dystonia,
myoclonus, tremor, and pyramidal syndrome secondary
to PRKCGmutations.3,9,26 In our cohort, myoclonus was
identified in 3 cases. This was clinically characterized as
occasional andmild, not requiring any treatment.Myoclo-
nus was identified early in the disease and remained mild
in the advanced cases. Unfortunately, none of the patients
reported having undergone electrophysiological recording,
and we are unable to comment further on this aspect;
therefore, further studies need to assess myoclonus as it
may be more frequent than previously reported.
We report 1 case with a combination of mild parkin-
sonism (presenting a stooped posture, gait freeing, rigid-
ity, and bradykinesia) in addition to cerebellar ataxia.
Interestingly, the rat animal model of PRKCG also exhib-
its a parkinsonian phenotype.27 Parkinsonism is rare and
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mild in SCA14.9,24 Our case as well as the Dutch9 and
French families24 presented with subtle parkinsonian syn-
drome in their early 20s that has not progressed with the
disease and did not require Levodopa treatment. The
combination of ataxia and parkinsonism is frequent in
neurodegenerative ataxias28; however, the combination
of autosomal dominant SCA and parkinsonism is mainly
observed in a parkinsonian form of SCA3 and sometimes
in SCA2,28,29 where the parkinsonism is present early in
the disease. In such cases, clinical differential diagnosis is
challenging and only genetic investigation can provide a
definite diagnosis. The sporadic neurodegenerative cere-
bellar ataxias with parkinsonism, such as multiple system
atrophy, present usually with a late-onset and a faster dis-
ease progression and are associated with autonomic
dysfunction.
In addition, cognitive impairment is only rarely
reported in SCA14, and if cognition is affected, only
minimal severity is reported,30 which was mirrored in
our series. However, a formal neuropsychology assess-
ment was conducted in symptomatic cases only limit-
ing our ability to characterize this further. We would
like to stress that all SCA14 cases that reported cogni-
tive impairment were before the age of 50 years, and
this complaint is not attributed to age-related associ-
ated disorders at present. Cognitive impairment has
been reported in other genetic forms of SCA and is
not only restricted to SCA1421; our study and previ-
ous reports warrant a further uniformed and system-
atic evaluation to validate these results.
Therefore, our data suggests that SCA14 diagnosis
in complex phenotypes should be considered in
patients with slowly progressive autosomal dominant
cerebellar ataxias, particularly when myoclonus, dys-
tonia, or cognitive impairment is present in the
absence of polyglutamine expansions. Furthermore, a
very mild severity and a slow progression of the addi-
tional features such as parkinsonism and myoclonus in
SCA14 can help differentiate them from other forms
of sporadic neurodegenerative disorders, such as mul-
tiple system atrophy (MSA).
Conclusion
We present one of the largest SCA14 cohorts of
patients reported contributing with novel variants and
supporting the distinct phenotype spectrum with spe-
cific cellular defects resulting from different types of
PRKCG mutations. Our cases extend the phenotype
and support the association of ataxia and severe dysto-
nia in SCA14. The association with severe peripheral
neuropathy needs confirmation in larger cohorts.
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